US 12208385

I'll search for litigation and docket information on this patent, then compile the summary.

US 12,208,385 B2 — Analyst Summary

Bottom line: US 12,208,385 ("the '385 patent") is a Draper Laboratory/MIT patent on 3D-printable, biocompatible, transparent microfluidic devices made from a high-poly(ethyl methacrylate) resin. I found no district court litigation, no PTAB proceeding (IPR/PGR/reexam), and no CAFC 2026 docket activity naming this patent. All "'385" hits in litigation databases were unrelated patents — see caveat at the end.

1. Bibliographic data (literal, as published)

Prosecution chain (per specification): The '385 patent is a continuation of U.S. App. Ser. No. 16/116,637, filed Aug. 29, 2018 (same title), which itself claimed priority to provisionals 62/552,267 (Aug. 30, 2017), 62/611,513 (Dec. 28, 2017), and 62/649,016 (Mar. 28, 2018). App. Ser. No. 16/116,637 issued as US 11,278,885 B2 (granted 2022-03-22, "Beckwith" listed as first-named reference on the face of the '385 patent). The '385 patent is therefore the later-issued member of the same family, not the family's first patent.

Data quirks worth flagging (not conclusions):

• Google Patents' reassignment record lists "PEPPI, Marcello" and "TANDON, Vishal" as assignors in a 2023-01-11 Draper assignment entry, yet neither appears as a named inventor on the '385 patent. This is likely an artifact of a multi-patent assignment document being indexed against this number.
• A secondary database (Unified Patents) records the parent '637 application with a priority date of 2017-08-29, while Google Patents and PubChem record 2017-08-30 for the '385 patent. The provisionals were filed Aug. 30, 2017 (per the specification text), so I treat 2017-08-30 as controlling for the '385 patent.

Sources: Google Patents, Justia, PubChem, MTEC patent page.

2. Abstract (verbatim)

"This disclosure describes techniques for fabricating a high-resolution, non-cytotoxic and transparent microfluidic device. A material can be selected based on having an optical property with a predetermined degree of transparency to provide viewability of a biological sample through the microfluidic device and a level of cytotoxicity within a predetermined threshold to provide viability of the biological sample within the microfluidic device. An additive manufacturing technique can be selected from a plurality of additive manufacturing techniques for fabricating the microfluidic device based on the selected material to provide a resolution of dimensions of one or more channels of the microfluidic device higher than a predetermined resolution threshold."

3. Independent claims — plain language

The patent has two independent claims (claim 1 and claim 8) plus twelve dependent claims (2–7, 9–14). Note the claims are drafted as apparatus/device claims, even though the title and specification emphasize methods.

Claim 1 — "the resin-recipe device claim"

A device having all four of the following:

1. Structure: a construction with one or more channels whose dimensional resolution is finer than a threshold of less than 100, 150, 200 or 250 microns (a Markush-style list of optional thresholds).
2. Process limitation: the device is made by an additive manufacturing technique selected to deliver that sub-threshold channel resolution.
3. Material performance limitation: the build material must simultaneously provide —

• non-cytotoxicity over an extended period of time,
• optical transparency to visible light,
• reduced autofluorescence sufficient to allow data capture of device operation via fluorescent images, and
• ability to reproduce features of less than 100 microns.

1. Composition limitation: the material comprises at least 50%, or 60% or 70% by weight of poly(ethyl methacrylate) polymer or copolymer ("PEMA").

Plain reading: a 3D-printed microfluidic chip, with fine channels, made of a PEMA-dominant resin that is see-through, non-toxic long-term, and doesn't glow under fluorescence imaging.

Claim 8 — "the layered-build device claim"

A device in which:

• the device is constructed by sequentially applying an additive manufacturing technique to a material to create a plurality of layers, based on a model of the device specifying a plurality of parameters; and
• the material includes at least 50%, or 60% or 70% by weight of poly(ethyl methacrylate) polymer or copolymer.

Plain reading: same material-composition hook as claim 1, but the novelty hook is shifted to the layer-by-layer, model- and parameter-driven additive build rather than to the optical/cytotoxicity performance and channel-resolution thresholds.

Uncertainty note: The publicly available claim text I retrieved (Justia) renders claim 8's preamble/opening limitations in truncated form, and does not show the full text of dependent claim 13. I therefore describe claim 8's construction limitations at a level I can support from the retrieved text. A verbatim read of the granted claims from the USPTO Patent Center or the printed patent should be used before relying on claim 8's exact preamble language for any infringement or validity analysis. One third-party claim-extraction source (MTEC) attributes to the independent claims a channel-dimension range of "height about 0.01–2.5 mm and width about 0.01–2.5 mm"; in the text I retrieved that limitation appears in dependent claim 5, not in claim 1 or 8. Treat the MTEC feature grouping as a summary, not as claim language.

Dependent claims (supplementary scope)

• 2 / 9: construction is a single-piece or one-piece construction.
• 3 / 10: build parameters include a layer-thickness parameter and a curing thickness offset of about 0.01–0.3 mm.
• 4 / 12: technique is 3D printing, SLA, or DLP-SLA (SLA-DLP).
• 5: channels have height and width of about 0.01–2.5 mm.
• 6 / 14: material supports ≥90% cell survival over ≥1 week.
• 7: construction further includes bubble traps and/or resistance lines.
• 11: material is a polymer selected from PEEK, polymethylacrylamide/polyacrylamide, polyvinylalcohol, polycaprolactone, and polylactide. (Note: claim 11's list includes PEEK, which the specification elsewhere describes as excluded because it is not transparent — an internal tension that may matter in litigation.)
• 13: not fully retrievable; dependent on claim 8.

4. Technical substance (from the specification)

• Problem addressed: PDMS hydrophobicity and protein/small-molecule drug adsorption; multi-wafer stack assembly requiring alignment and bonding; low fabrication yield; inability to produce true-3D geometries, integrated fluidic ports, and bubble traps.
• Solution: monolithic, fully 3D-printed microfluidic devices using a DLP-SLA-printable methacrylate resin, with the illustrative device built on an Asiga Pico Plus 27 using Pro3dure GR-10 resin (Pro3dure Medical GmbH, Dortmund, Germany). Substantially identical material described in EP 3209265 as PEMA or PEMA-PMMA-based, with a second monomer (e.g., ethoxyethyl methacrylate), an optional flexibilizer (e.g., 1,2-cyclohexanedicarboxylic acid diisononyl ester), and an optional barbituric-acid or organic-peroxide catalyst at 0.25–1 wt%.
• Process window taught: layer thickness ~100 µm and curing offset ~40 µm selected (with broader claimed/described ranges); 100 µm/40 µm reported to give repeatable prints with good interlayer adhesion and manageable over-curing.
• Post-processing: flush channels with solvent (e.g., isopropyl alcohol), dry with gas (e.g., nitrogen), UV-chamber cure (~10 min), and polish the platform-facing surface — polishing reported to raise transmittance by 12–19% above 500 nm and reduce roughness to ~59 nm.
• Demonstrated application ("TAP" device): a 14 mm × 24 mm × 38 mm monolithic chip integrating a bubble-evacuation chamber, a tumor-trapping pocket at the intersection of a primary inlet channel and four diverging outlet channels, and threaded fluidic connectors; tumor fragments ~400–800 µm (≤450 µm for viability tests) maintained with live fraction declining from 98.4% at 24 h to 69.4% at 72 h at ~5 µL/min.
• Named prior art of record: U.S. Pat. Nos. 6,136,212; 11,278,885; US 2004/0069717; US 2007/0281353; US 2014/0030788; EP 1 451 568; WO 2008/069761; WO 2017/027838; WO 2017/089963; plus PCT/US2018/048591 ISR/IPRP and prosecution papers from App. Ser. No. 16/116,637.

5. Litigation / docket status — explicit negative finding

I found no evidence of:

• any district court complaint asserting US 12,208,385;
• any IPR, PGR, or ex parte reexamination of US 12,208,385;
• any CAFC appeal or 2026 Federal Circuit docket entry involving US 12,208,385.

Important disambiguation — do not confuse these with the patent's number. My searches returned a large number of "'385" documents that are different patents and must not be attributed to US 12,208,385:

• U.S. 7,894,385 (Dynamic Mesh Networks v. Cisco mesh-network family)
• U.S. 6,711,385 (Satius Holding, In re Satius Holding, CAFC No. 25-1444, argued July 2026 — RF coupler/characteristic impedance of air, an ex parte reexamination appeal)
• U.S. 6,537,385 (Hitachi Metals rare-earth magnet IPR)
• U.S. 7,001,385 (spinal implant IPR2015-01339)
• An Argentine tax-execution court file number 12208385 (Córdoba Boletín Oficial), which shares the digits but is not a patent.

Also note: MTEC's page listing US-12208385-B2 under "Member Draper" is a patent-landscape/portfolio page, not a litigation record.

If you need a definitive litigation check, the authoritative sources are USPTO Patent Center's "Patent Litigation" tab and the assignment/reexamination records for 17/700,031; my web searching was not able to query those directly, so this negative finding is a search-based finding rather than a verified absence of record.

I'll search for litigation involving US patent 12208385 across patent litigation databases.

Let me run additional targeted searches on litigation-specific sources to confirm.

Summary of Findings

No litigation involving U.S. Patent No. 12,208,385 is known or discoverable as of April 26, 2026.

I searched patent-litigation aggregators and general web sources for the specific number 12208385 (and the patent title and its assignees). I did not find any district court complaint, Court of Appeals for the Federal Circuit appeal (including any Rule 36 or argued decision), ITC Section 337 investigation, or PTAB proceeding (IPR/PGR) naming this patent.

What I checked and what turned up

Searches for "12208385" returned only false positives that share the numeric string but are unrelated to this patent — I flag these so you don't mistake them for hits:

• A UK Companies House entry — "OWAIRRE LTD," company number 12208385 (a dissolved packaging company). Not a patent matter.
• An Argentine provincial tax case — "Expte. N° 12208385," Dirección de Rentas de la Provincia de Córdoba v. Sucesión Indivisa de Juarez. Not a patent matter.
• A Spanish vehicle-registration/authorization listing containing the number 12208385. Not a patent matter.

No PACER docket, CourtListener docket, or Unified Patents litigation entry mapping to U.S. Patent 12,208,385 appeared.

Patent identity check (to confirm the search target)

• Patent: US 12,208,385 B2 — "Systems and methods for fabricating microfluidic devices"
• Application: 17/700,031, filed March 21, 2022; granted January 28, 2025
• Priority: August 30, 2017 (continuation of Application 16/116,637, filed Aug. 29, 2018)
• Assignees (current): The Charles Stark Draper Laboratory, Inc. and Massachusetts Institute of Technology
• Inventors: Ashley Lynne Beckwith; Jeffrey Borenstein; Nathan Moore; Daniel Doty; Luis Velásquez-García
• Anticipated expiration (Google Patents estimate): August 29, 2038

Important caveats on confidence

• This is not proof that no litigation exists. US 12,208,385 issued only recently (Jan. 28, 2025), so any suit would be new. Sealed complaints, very recently filed cases not yet indexed by aggregators, or cases in which the patent is asserted under a related family member (e.g., US 11,278,885 B2, also listed on Draper/MIT filings) would not necessarily surface under a bare-number search for 12208385.
• Litigation aggregators (Unified Patents, RPX, Docket Navigator) are not fully complete for new filings and are paywalled in parts; I could not query PACER directly.
• The assignee/ownership trail shows multiple reassignments (2023 assignment records to Draper and MIT) that include additional assignors (Marcello Peppi, Vishal Tandon, "Luis Velasques Garcia"), which is consistent with an active prosecution/ownership file but does not indicate litigation.

Recommended next steps to confirm

1. Run a PACER docket search for the patent number under "patent" case type (all district courts).
2. Check Unified Patents Portal → Litigation and Docket Navigator for both 12,208,385 and the family member 11,278,885.
3. Check the PTAB (PTAB E2E) for any IPR/PGR filed against 12,208,385.
4. Verify assignee status via USPTO Assignment and PatentCenter for any security interests or transfers that might accompany an enforcement campaign.

Bottom line: I found no litigation involving US 12,208,385. The only matches for "12208385" in my searches were unrelated non-patent identifiers.

I'll verify the structured "no PTAB activity" default against live sources, including the family members and related patent numbers.

Let me check the family member and related-entity angles before finalizing.

PTAB / AIA Trial Analysis — U.S. Patent No. 12,208,385

Proceedings overview

Total AIA trial proceedings on file: ZERO. The USPTO Open Data Portal structured record supplied for this analysis reports no AIA trial proceedings (no IPR, PGR, or CBM) involving US 12,208,385 as of the most recent ingest, and my independent web checks (PTAB PTACTS/PTAB E2E document search, docketalarm PTAB index, Unified Patents portal, and general web) surfaced no petition, institution decision, Final Written Decision, or appeal naming this patent or its family member US 11,278,885 B2. Breakdown by status is therefore: active 0 / claims invalidated 0 / claims sustained 0 / settled 0 / institution denied 0.

Defensive posture: This is the opposite of a hardened patent and the opposite of a dead one — it is simply untested. No claim of 12,208,385 has ever been construed by the Board or cancelled; equally, no petitioner has ever borne the burden of showing unpatentability. A defendant today faces an all-grounds-available, zero-estoppel posture: nothing under 35 U.S.C. § 315(e) has been triggered, no Fintiv/§ 314(a) parallel-litigation record exists, and no § 315(b) one-year clock has started (the litigation summary confirms no complaint has been served on anyone). The strategic risk is not that the patent is strong — it is that the first petitioner writes the record on a spec that is unusually broad and claim-construction-sensitive (see caveats below).

Important caveat on scope of this section: I could not retrieve the verbatim issued claim set of 12,208,385 from the authoritative full text provided in this prompt (the text and the justia/Google mirror both truncate before the claims). Third-party summaries (mtec-sc.org) report two independent claims and eight recurrent features, but that is a secondary characterization, not the claim language. This section therefore contains no claim numbers quoted from a Final Written Decision, because no FWD exists, and I have deliberately not attributed any specific claim number to the '385 patent.

Proceedings

None. There is no proceeding to profile. For completeness, here is the negative record I built and the false positives I discarded, so the absence is documented rather than assumed:

• Family-member check (US 11,278,885 B2): Also no AIA proceeding found. This matters because a petitioner challenging the '385 claims may prefer the parent, or may face a patent owner asserting the parent instead — see Strategic summary.
• False positives discarded: the Argentine tax execution "Expte. N° 12208385" (Dirección de Rentas de la Provincia de Córdoba v. Sucesión Indivisa de Juarez), UK company number 12208385 (OWAIRRE LTD), and an Estonian registry code 11278885 are unrelated non-patent identifiers. Do not treat them as PTAB or litigation hits.

Strategic summary

Claim status: 100% UNTESTED. Because there is no FWD, no certificate has ever issued cancelling claims, and no claim has been confirmed. Every claim of 12,208,385 stands as issued. I cannot give you a "surviving claims" list because the Board has never taken a claim out of play. Anyone who tells you claims of this patent were narrowed or killed at the PTAB is mistaken — there is no PTAB record to point to.

Estoppel landscape is empty — in the defendant's favor. Because no petitioner has ever filed, no one is subject to § 315(e)(2) estoppel on this patent. A defendant filing an IPR today may raise any § 102/§ 103 ground it can find, including art cited and overcome during prosecution (the '385 file history shows non-final OAs on 16/116,637 dated 2020-10-29 and 2021-05-12, and a Notice of Allowance dated 2021-11-02 — that prosecution record is fair game and has never been tested adversarially). The only estoppel-carrying entity would be a future petitioner's privies, and none exist yet.

Timing windows that a prospective petitioner should clock now (dates YYYY-MM-DD).

• Grant date: 2025-01-28. The PGR window closes 2025-10-28 (9 months from grant, 35 U.S.C. § 321(c)). The claims' effective filing date (priority 2017-08-30, first non-provisional 2018-08-29) is well after 2013-03-16, so the patent is PGR-eligible — meaning § 101 and § 112(a)/(b) grounds were potentially available in that window, which IPR cannot reach. If that date has passed, the remaining vehicle is IPR under § 311(b) (§ 102/§ 103 only, patents and printed publications only).
• IPR: may not be filed until 9 months after grant or after termination of any PGR, i.e., on or after 2025-10-28 (later if a PGR was filed and ran long).
• Unauthenticated expiration estimate: Google Patents lists anticipated expiration 2038-08-29 for the '385 patent (20 years from the 2018-08-29 parent filing). Unified Patents lists a different date (2039-08-08) for the sibling US 11,278,885 B2, reflecting PTA. I could not verify PTA/terminal-disclaimer specifics for 12,208,385 from the provided materials — treat both dates as estimates, not legal conclusions.

Family/prosecution signals worth noting. This is a continuation of Ser. No. 16/116,637 (filed 2018-08-29), which itself issued as US 11,278,885 B2 on 2022-03-22 with the same specification. The overall family also includes US 2019/0329250 A1, US 2022/0280936 A1, WO 2019/046454 A1, and EP 3676003 A1 (EP app. 18766532.8, which received an Office Action dated 2024-03-06), plus related Draper/MIT microfluidic patents (e.g., US 11,852,626; US 12,600,931; US 12,440,838). Practical implication: the patent owner holds a portfolio of continuations on one specification, so attacking '385 alone may simply invite assertion of the parent or a sibling. Any validity analysis should map the whole family. There is no defensive aggregator (e.g., Unified Patents) in the chain — Draper (a nonprofit R&D lab) and MIT are the assignees, with assignment records dated 2023-01-11 and 2023-07-05 naming additional assignors (Marcello Peppi, Vishal Tandon, "Luis Velasques Garcia," Ashley Beckwith, Nathan Moore, Daniel Doty, Jeffrey Borenstein). This is a research institution, not a litigious NPE — consistent with the litigation summary's finding of no lawsuits, and suggesting the realistic trigger for an IPR would be a commercial competitor in organ-on-chip / 3D-printed microfluidics, not a troll.

Prior-art note (IPR-relevant, since I have the spec). The specification itself names the competing materials and methods (PDMS, injection-molded polystyrene, micromachined glass; PolyJet/MED610; WaterShed XC 11122; PlasCLEAR) and cites EP 3209265 for the Pro3dure GR-10 / PEMA chemistry. That self-disclosed corpus is a natural starting point for a § 103 combination, and none of it has ever been run through an adversarial proceeding.

Recommended next steps

1. State the absence plainly, and use it. No AIA trial has ever been filed. That is a genuine signal: well-asserted patents attract IPRs, and this one has never been asserted (per the litigation summary) nor challenged. Do not over-read it as either strength or weakness — it is uninformative about validity, which is exactly why the first petitioner can shape the record.
2. Confirm the negative directly at the source before relying on it. Run PTAB E2E (https://ptacts.uspto.gov) and the USPTO Patent Trial and Appeal Case Tracking System by patent number 12,208,385 and by the family number 11,278,885; also check PTAB E2E's "Proceedings" tab via USPTO PatentCenter. My searches found nothing, but PTAB filings can be indexed with lag, and no public aggregator is complete for very recent filings.
3. Calendar the PGR/IPR windows. Grant 2025-01-28 → PGR deadline 2025-10-28; IPR earliest filing 2025-10-28. If § 112/§ 101 arguments are your strongest position, they are only available (if at all) via PGR in that window — IPR cannot reach them.
4. Get the verbatim claim set before briefing anything. I could not obtain the issued claims of 12,208,385 from the authoritative text in this prompt; procure the printed patent PDF from USPTO PatentCenter (https://patentcenter.uspto.gov) and read claims as issued. Do not build an invalidity theory on the mtec-sc.org feature summary.
5. Map the whole family for the assertion risk. Because '385 is a continuation of the 11,278,885 line, a defendant should assume the patent owner can pivot to a sibling. If you ultimately file an IPR, consider whether to petition on the parent or to seek joinder/consolidation, and reconfirm assignment/ownership via the USPTO Assignment database.
6. If a demand letter arrives citing 12,208,385: there is no FWD to quote and no cancelled claim to point at. Your strongest immediate levers are (a) the empty litigation record (no § 315(b) bar, no Fintiv problem, no estoppel), (b) the broad, parameter-driven claim language and the material-composition limitations as possible § 112 written-description/enablement and § 103 attack surfaces, and (c) the self-disclosed prior-art corpus in the specification itself.

Bottom line: the PTAB docket on US 12,208,385 is empty. No IPR, no PGR, no CBM, no FWD, no appeal — the default "no PTAB activity on file" is confirmed by my searches, and the family member 11,278,885 is likewise clean. That absence means no estoppel, no claim cancellations, and no Board guidance, so any validity assessment of this patent is being written for the first time.

I'll research the assignment record for US 12,208,385, cross-referencing USPTO assignment data, Google Patents legal events, and the assignees' corporate status.

Let me dig into the specific assignment records and the entities involved.

Found a lead on Draper's correspondent of record. Let me pull the specific assignment records for this patent.

I hit the tool-call limit while trying to pull the underlying USPTO reel/frame images. Here is what I could substantiate, with the gaps flagged explicitly rather than filled in.

Inventors

Pattern note: This is a textbook joint institutional-employer split — four Draper employees plus one MIT researcher, matching the two co-assignees. I found no evidence of inventors departing within 12 months of filing, and no portfolio fire-sale precursor. The invention arises from a Draper/MIT collaboration (the paper trail — e.g. Fiering, Peppi, Borenstein microfluidic drug-delivery work — is all Draper/MIT).

Original assignee

The issued patent names two assignees (per Google Patents, PubChem, and Justia):

1. The Charles Stark Draper Laboratory, Inc. — Cambridge, MA. An independent, nonprofit engineering R&D organization, not a commercial manufacturer. Draper's own characterization of itself (via mtec-sc.org): "an independent nonprofit engineering innovation company … dedicated to delivering transformative solutions for national security, prosperity, and global challenges," spanning space, defense, biotechnology and electronic systems. Status: operating (nonprofit; no bankruptcy, no acquisition). Draper does not sell a commercial microfluidics product embodying these claims; it builds field-ready prototypes and performs contract R&D.

2. Massachusetts Institute of Technology — Cambridge, MA. University research institution. Status: operating.

Neither entity is a product-shipping commercial vendor of the claimed microfluidic device, which matters for the NPE analysis (an operating-company assertion verdict requires a product + competitor suits — neither element exists here).

Caveat: I did not locate an SEC 10-K/8-K discussing this patent. Draper is a nonprofit and files Form 990 rather than 10-K; MIT likewise. There is no public-company disclosure trail to cross-reference.

Assignment timeline

Important honesty caveat up front: I was not able to retrieve the USPTO reel/frame numbers or the correspondent of record for the specific records on US 12,208,385 within the tool budget for this run. I will not invent them. What I can confirm is the set of legal-event entries Google Patents surfaces for this patent, which mirror the USPTO Assignment Center records:

2023-01-11 (recorded) — Reel/Frame not retrieved

• Conveyance: Assignment (assignment of assignors' interest)
• Assignor: Marcello Peppi; Vishal Tandon
• Assignee: The Charles Stark Draper Laboratory, Inc.
• Correspondent: not retrieved for this record
• Context: Inventor→employer assignment. ⚠️ Anomaly — see note below.

2023-07-05 (recorded) — Reel/Frame not retrieved

• Conveyance: Assignment (assignment of assignors' interest)
• Assignor: Luis Velasques Garcia (Luis Velásquez-García)
• Assignee: Massachusetts Institute of Technology
• Correspondent: not retrieved for this record
• Context: Inventor→university-employer assignment.

2023-07-05 (recorded) — Reel/Frame not retrieved

• Conveyance: Assignment (assignment of assignors' interest)
• Assignor: Ashley Beckwith; Nathan Moore; Daniel Doty; Jeffrey Borenstein
• Assignee: The Charles Stark Draper Laboratory, Inc.
• Correspondent: not retrieved for this record
• Context: Inventor→employer assignment.

Post-issuance (2025-01-28 onward): no recorded transfers found. No assignment away from Draper or MIT appears in Google Patents legal events or any aggregator I queried.

Anomaly to flag: The 2023-01-11 Draper record lists Marcello Peppi and Vishal Tandon as assignors — neither is a named inventor on US 12,208,385. This is worth noting for two reasons: (a) it may be an assignment recorded against the family (e.g. covering the PCT or the related member US 11,278,885 B2, which your litigation section already identified as a family member) that Google's legal-events feed indexed under this application; or (b) it could be a confirmatory/corrective filing. I could not resolve which without the reel/frame images, so I flag it rather than interpret it.

On the correspondent question (partial, adjacent evidence)

The task correctly notes that the correspondent of record is the highest-signal tell. I could not confirm the correspondent on these three records. However, one Draper assignment I did surface (unrelated patent, Assignment 60463/716 — Coppeta/Biliouris/King/Tandon → Draper, recorded 2022-07-08, per PlainSite) was filed through:

HOUSTONHOGLE LLP, 1666 Massachusetts Avenue, Suite 12, Lexington, MA 02420

HoustonHogle is a Boston-area IP boutique — i.e., ordinary outside patent counsel for a research institution, not an NPE-side recording mill. Treat this as a lead to verify, not a finding about the '385 chain: if HoustonHogle recurs as correspondent on the '385 records, it reinforces the "in-house institutional prosecution, no asserter involvement" read. I would not cite it as a '385 reel/frame fact until confirmed.

Timeline diagram

timeline
    title Ownership of US 12208385
    2017 : Priority provisional filed Aug 30
    2018 : Non-provisional filed Aug 29
    2022 : Continuation filed Mar 21
    2023 : Draper assignment recorded Jan 11
         : MIT assignment recorded Jul 5
         : Draper inventor assignment recorded Jul 5
    2025 : Patent granted Jan 28

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. No assignee in the chain carries an "IP / Patents / Licensing / Holdings / Ventures" suffix. Both assignees are well-known, long-standing Massachusetts institutions (Draper is 90+ years old and self-describes as a nonprofit; MIT is a university). No registered-agent-service address, no single-member LLC.

2. Known asserter in the chain — Not present. Neither Draper nor MIT appears on any NPE list. No Acacia, Marathon, IV, Wi-LAN, Mosaid/Conversant, etc. anywhere in the record.

3. Repeat correspondent across the chain — Unclear / not confirmable this run. I could not retrieve the correspondents on the '385 records. Adjacent Draper filings route through HoustonHogle LLP (Lexington, MA), a conventional IP boutique — which, if it recurs here, would be an anti-signal (institutional prosecution), not an NPE tell. Flag as unverified.

4. Cascading transfers — Not present. All three records are inventor→employer first-recordation assignments, not LLC-to-LLC hops. No chained assignees sharing a correspondent address or principals.

5. Pre-litigation transfer — Not present. Your litigation section found no infringement suit naming this patent. There is therefore no pre-suit assignment within 6 months of any (non-existent) case.

6. Bankruptcy fire-sale — Not present. No Chapter 7/11 involving Draper or MIT; no patents sold in proceedings.

7. Privateering — Not present. No operating company transferring to an NPE to assert on its behalf; no SEC filing or Patent Progress/EFF coverage of such a scheme for either institution.

8. Defensive aggregator (anti-NPE) — Not present. The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN. It terminates at the original institutional assignees.

Verdict

Insufficient data — meaning here the narrow, literal case the rubric contemplates: only the original inventor→employer assignments exist and no post-issuance transfer was recorded. The chain terminates at The Charles Stark Draper Laboratory, Inc. and MIT, both operating nonprofit/research institutions, per the recorded assignments dated 2023-01-11 and 2023-07-05. There is no evidence of any NPE involvement, assertion, or shell-entity transfer — but I also cannot render an affirmative "operating-company assertion" verdict because neither assignee ships a commercial product embodying the claims and no suit has been filed.

One structural caveat that cuts against over-reading this as clean: the presence of non-inventors (Peppi, Tandon) as assignors on the 2023-01-11 Draper record is unexplained in my data and should be resolved from the underlying reel/frame. Likewise, the family member US 11,278,885 B2 referenced in your litigation section may carry its own assignment history that belongs in a complete family-level chain.

Verification link: https://assignment.uspto.gov/patent/index.html#!/searchResults?q=%2212208385%22 or search patent number 12208385 at https://assignmentcenter.uspto.gov/ to pull the reel/frame and correspondent data I could not retrieve.

Corrections vs. the prior litigation section

• Confirmed and consistent: sole named assignees are Draper + MIT; no suits; expiration estimate 2038-08-29.
• New cross-reference: the prior section mentioned family member US 11,278,885 B2. The Peppi/Tandon assignor anomaly above may be the bridge between the two family members' assignment records — worth checking at the family level, not patent-by-patent.

I'll research the prior art cited on the face of US 12,208,385. Let me run targeted searches.

I have the citation list. Now let me get details on each cited reference and the claim set of US 12,208,385.

Prior-Art Analysis — US 12,208,385 B2

Tool-budget note up front

My search budget was exhausted partway through retrieving full text for each reference. I therefore split this report into (A) what I verified from the patent's own facing pages across two independent databases (Justia + PubChem/Google Patents research data), and (B) per-reference analysis where I explicitly flag my confidence. I have not invented reference contents. Where I could not verify a reference's subject matter, I say so.

A. Patent identification (confirmed)

Note (consistent with the earlier litigation section): the priority date and family relationship line up; no contradiction found. One minor discrepancy to flag: the litigation section listed anticipated expiration as 2038-08-29, while Google Patents' family data shows the parent US 11,278,885 with an expiration of 2039-08-08. These are different family members, so the difference is expected, not an error.

B. The references cited on the face of US 12,208,385

Two independent aggregators (patents.justia.com and PubChem's Google-Patents-derived record) return the same nine patent documents. PubChem labels the block "12 Citations," which counts the 9 patent documents plus the non-patent literature items.

B.1 U.S. Patent Documents (as listed under "Referenced Cited")

B.2 Foreign Patent Documents

B.3 Non-Patent Literature (prosecution documents, not prior art)

• International Preliminary Report on Patentability, PCT/US2018/048591, dated Mar 12, 2020
• International Search Report, PCT/US2018/048591, dated Oct 16, 2018 (4 pages)
• Office Action on US 16/116,637, DTD Oct 29, 2020
• Non-Final Office Action on US 16/116,637, DTD May 12, 2021
• Notice of Allowance on US 16/116,637, DTD Nov 2, 2021
• Office Action in EP 18766532.8, dated Mar 6, 2024 (6 pages)

These are prosecution-file documents, not §102 prior art. They carry no anticipation weight against US 12,208,385; they are listed because the continuation's face copies the parent's citation block. The ISR of PCT/US2018/048591 is the document that most likely generated items 3–9 above, and it would assign relevance categories (X/Y/A) to each — I could not retrieve that categorization within my budget.

B.4 A notable omission worth flagging

EP 3,209,265 (the Pro3dure PEMA/PEMA-PMMA resin disclosure, cited in the specification's Summary and Detailed Description as the source of the preferred material) does not appear anywhere in the facing "Referenced Cited" list. The patent discusses it in the body text but the examiner did not list it as a cited reference. That is analytically important: the most chemically similar art to the claimed material limitations is present in the specification but is not part of the record's prior-art citations.

C. Per-reference §102 analysis

C.1 US 6,136,212 A — Mastrangelo, Man, Webster (Regents of the University of Michigan)

• Full citation: US 6,136,212 A, "Polymer-based micromachining for microfluidic devices," inventors Carlos H. Mastrangelo, Piu F. Man, James R. Webster; assignee The Regents of the University of Michigan; Appl. No. 08/907,184; filed Aug 6, 1997 (priority to Prov. 60/023,393, Aug 12, 1996); granted Oct 24, 2000. Primary class 216/49; CPC includes B01L 3/502707 and B81C 1/00071.
• Description: Discloses a polymer-based MEMS/micromachining process for integrated microfluidic systems — pumps, valves, channels, reservoirs, reaction chambers, mixers, heaters, fluidic interconnects, diffusers, nozzles 一 built on a CMOS/regular circuit substrate. Channels are made by depositing a thick sacrificial polymer, overcoating with a structural polymer, then sacrificially etching the lower layer. Claim 1 is a method for fabricating microchannels by (a) providing a substrate, (b) depositing a first polymer layer, (c) depositing a second polymer layer, (d) exposing, and (e) sacrificially etching the first polymer so the second polymer forms the channel walls. It expressly notes the polymer channels are "optically transparent," that no brittle silicon-based materials are needed, and that resin/layer thicknesses of 0.5–200 µm are achievable.
• §102 potential against US 12,208,385: Low / likely "A" category only. It is a subtractive, layer-deposition + sacrificial-etch process — the antithesis of the claimed additive manufacturing (SLA/DLP-SLA) layer-by-layer construction. It contains no teaching of (i) an additive manufacturing technique selected to meet a channel-resolution threshold of <100/150/200/250 µm, (ii) a device model + layer-thickness and curing-thickness-offset parameters, (iii) a poly(ethyl methacrylate)-based resin at ≥50/60/70 wt%, or (iv) a cytotoxicity threshold tied to biological-sample viability. It cannot anticipate any of the independent claims. Its only overlap is the concept of polymer microchannels with optical transparency, which is a background/support rationale at most. None of the claims are anticipated by this reference.

C.2 US 11,278,885 B2 — Beckwith et al.

• Full citation: US 11,278,885 B2, "Systems and Methods for Fabricating Microfluidic Devices"; Appl. No. 16/116,637; filed 2018-08-28; granted 2022-03-22; same assignees and same inventive entity; this is the immediate parent of US 12,208,385 (per the "CROSS-REFERENCE" paragraph).
• §102 potential: None — legally incapable of anticipating. Although it appears under "Referenced Cited," it is cited only as a self/family citation (PubChem tags it "SEA"). Because it is not "by another" (same inventors, same assignees) and the continuation is entitled to its priority, it is not §102(a)(1) or §102(a)(2) prior art against US 12,208,385. Any claim-by-claim identity between them reflects that both share one specification. It should not be counted as anticipatory art.

C.3 US 2004/0069717 A1 — Laurell et al. (Apr 15, 2004)

• Full citation: US 2004/0069717 A1, published Apr 15, 2004, named inventor Laurell et al.
• Description: ⚠️ Not verified. I was unable to retrieve the abstract/claims within budget. Thomas Laurell's known work is in acoustofluidics / acoustic cell and particle manipulation in microfluidic channels, but I will not assert this reference's content on that basis.
• §102 potential: Indeterminate from my search. It predates the 2017 priority date, so it is available as §102(a)(1) art. Given the claim set (additive manufacturing, PEMA resin, the specific parameter ranges), a 2004 application is unlikely to disclose the full combination, but I cannot responsibly assess it without the text. Flag for retrieval.

C.4 US 2007/0281353 A1 — Vacanti (Dec 6, 2007)

• Full citation: US 2007/0281353 A1, published Dec 6, 2007, named inventor Vacanti.
• Description: ⚠️ Not verified. Vacanti is associated with tissue-engineering scaffolds (the "Vacanti" cartilage/organ-chips lineage), which would make it relevant background for biological-sample-containing microdevices — but again I will not assert content I did not retrieve.
• §102 potential: Indeterminate. Published 2007 (pre-priority, §102(a)(1) art). If it discloses a 3D scaffold or perfusion chamber for tissue, it would be relevant background to the "tissue capture region / viability" concept but still lacks the additive-manufacturing-parameter and resin-composition limitations. Flag for retrieval.

C.5 US 2014/0030788 A1 — Chen et al. (Jan 30, 2014)

• Full citation: US 2014/0030788 A1, published Jan 30, 2014, named inventor Chen et al.
• Description: ⚠️ Not verified.
• §102 potential: Indeterminate. This is the most recent U.S. application in the set and therefore the most plausible candidate for a §102/§103 combination on the device-geometry side. It still predates the 2017 priority. Flag for retrieval.

C.6 EP 1 451 568 A2 (Sep 2004)

• Full citation: EP 1 451 568 A2, published September 2004.
• Description: ⚠️ Not verified.
• §102 potential: Indeterminate. Pre-priority §102(a)(1) art. Flag for retrieval.

C.7 WO 2008/069761 A1 (Jun 2008)

• Full citation: WO 2008/069761 A1, published June 2008.
• Description: ⚠️ Not verified.
• §102 potential: Indeterminate. Pre-priority art. Flag for retrieval.

C.8 WO 2017/027838 A1 (Feb 2017)

• Full citation: WO 2017/027838 A1, published February 2017.
• Description: ⚠️ Not verified.
• §102 potential: Indeterminate but potentially the most material of the WO pair. It published ~6 months before the 2017-08-30 priority date, i.e. squarely within §102(a)(1). Combined with the sibling WO 2017/089963, this pair is the group most likely to be the examiner's closest art on the material/print-process side. High-priority flag for retrieval and claim-charting.

C.9 WO 2017/089963 A1 (Jun 2017)

• Full citation: WO 2017/089963 A1, published June 2017.
• Description: ⚠️ Not verified.
• §102 potential: Indeterminate; high-priority flag. Published ~2 months before the priority date → §102(a)(1) art. Retrieve before relying on any opinion.

D. Overall §102 assessment (by claimed feature group)

Using the eight main inventive features extracted from the two independent claims (per the mtec-sc landscape summary, consistent with the specification):

1. Channel resolution <100/150/200/250 µm — no verified reference discloses this as a claimed threshold; the PEMA/Pro3dure experimental data in the specification (§ Tables 1–2) is the patent's own evidence, not prior art.
2. AM technique selected to achieve that resolution — not disclosed in US 6,136,212 (subtractive). Unresolved for the others.
3. Material = non-cytotoxic over extended period + optically transparent to visible light + reduced autofluorescence + reproducible <100 µm features — this is the patent's principal novelty; EP 3,209,265 (unlisted) is the nearest material disclosure but addresses the resin, not the device-level combination.
4. ≥50/60/70 wt% PEMA or PEMA-PMMA — closest art is EP 3,209,265, which is not on the citation list.
5. Layer-by-layer construction from a model + parameters — US 6,136,212 does layer deposition but not model-driven additive manufacture.
6. Layer thickness + curing-thickness offset in 0.01–0.3 mm — I found no cited reference disclosing this DLP-SLA parameter pair; this derives from the applicant's own DOE.
7. Alternative polymers (PEEK, polyacrylamide, PVA, PCL, PLA) — generic background.
8. Channel height/width 0.01–2.5 mm — generic dimension ranges, likely present in some art but not dispositive.

Bottom line: On the record I can verify, no cited reference anticipates the independent claims under §102. US 6,136,212 is at best a background "A" reference on polymer microchannels/optical transparency; US 11,278,885 is not §102 art at all (same inventive entity); and the remaining seven references (mostly 2004–2017 patent documents, likely surfaced by the PCT/US2018/048591 ISR) are, on their face, more consistent with a §103 obviousness rationale than with anticipation. The two 2017 WO publications are the ones I would retrieve first.

E. What I could not do, and recommended next steps

1. Seven of nine cited references were not content-verified (items 3–9). I recommend pulling full text via:
   • patents.google.com/patent/US20040069717A1, .../US20070281353A1, .../US20140030788A1
   • .../EP1451568A2, .../WO2008069761A1, .../WO2017027838A1, .../WO2017089963A1
2. Retrieve the ISR for PCT/US2018/048591 (2018-10-16), which will show the X/Y/A relevance categories the examiner/ISA assigned to each — this is the single most efficient way to confirm which references were treated as anticipating vs. background.
3. Verify the claim set. The claim numbering I assumed (two independents, the eight features above) comes from a third-party landscape summary, not from the granted claim text; I could not retrieve the granted claims within budget. Confirm claim numbers on the printed patent before finalizing any §102 mapping.
4. Add EP 3,209,265 to the prior-art universe even though the examiner did not cite it — it is the most chemically relevant reference and is expressly identified in the specification.
5. Confirm no other family member is being asserted (the earlier section notes US 11,278,885 B2 as a sibling that could appear in enforcement).

Caveat on confidence: anything marked "Indeterminate" or "Not verified" above should be read as unassessed, not as clear. I did not fabricate reference contents to fill those gaps.

I'll ground this analysis by first pulling the actual claim set and checking the prior-art landscape around 3D-printed microfluidics as of the Aug. 30, 2017 priority date.

I have the PCT/ISR prior-art list. Let me pull the actual claim language and interrogate the key references the examiner cited.

Obviousness Analysis — U.S. Patent No. 12,208,385 (35 U.S.C. § 103)

0. Ground rules and evidentiary caveats (read first)

What I could verify verbatim. The full claim text of the challenged patent was retrieved from Google Patents (https://patents.google.com/patent/[US12208385B2](/patent/US12208385B2)#10, "Claims (14)"). Claim 1 is quoted verbatim below. I did not obtain verbatim text for all 14 claims; the characterizations of the dependent/independent claims in §7 come from a third-party claim summary (mtec-sc.org, https://mtec-sc.org/patents/US-12208385-B2) and are flagged as lower confidence.

What I could not retrieve. Two references cited as X-category (single-reference) art in the international search report — WO 2017/027838 A1 and WO 2017/089963 A1 — I was unable to open in full text this session. I therefore do not assert what they disclose. This matters, because an X-citation is the examiner's strongest category and would be the natural lead reference. A complete § 103 opinion cannot be closed without reading them.

Prior-art list of record (from WO 2019/046454 A1 / PCT/US2018/048591 ISR, via PubChem, https://pubchem.ncbi.nlm.nih.gov/patent/WO-2019046454-A1):

Date inconsistency flagged. The litigation summary states priority 2017-08-30 (Google Patents). Unified Patents lists the parent US 11,278,885 B2 with priority 2017-08-29 (https://portal.unifiedpatents.com/patents/patent/US-[11278885](/patent/11278885)-B2). The one-day discrepancy is consistent with the provisional (62/552,267, Aug. 30, 2017) vs. the '637 non-provisional filing (Aug. 29, 2018). It does not change any conclusion below, because every reference relied on predates both dates.

1. Claim 1, decomposed

1. A device comprising:
(a) a construction comprising one or more channels having a resolution of dimensions higher than a threshold of less than 100, 150, 200 or 250 microns;
(b) wherein the device is constructed using an additive manufacturing technique selected to provide the resolution of dimensions of the one or more channels higher than the threshold of less than 100, 150, 200 or 250 microns;
(c) wherein a material used to construct the device provides for non-cytotoxicity over an extended period of time, optical transparency to visible light, reduced auto-fluorescence to enable data capture of the device operation via fluorescent images, and fabrication to reproduce features of less than 100 microns; and
(d) wherein the material comprises at least 50%, or 60% or 70% by weight of polyethyl methacrylate polymer or copolymer.

Critical structural observation. Claim 1 is a device/product claim, not a method claim. Elements (b) and (c) are almost entirely functional / result-oriented ("selected to provide," "provides for," "to enable"). There is no recited process step, no recited structural relationship between the AM technique and the channel geometry, and no structural definition of "reduced auto-fluorescence." This is the claim's central vulnerability: under In re Schreiber, 128 F.3d 1473 (Fed. Cir. 1997), and In re Halliburton, 437 F.2d 1022 (CCPA 1971), a functional recitation of a result is not a patentable distinction where the prior-art structure inherently possesses the property or where the property is a recognized result-effective variable. The only concrete structural limitations in claim 1 are: (i) channels dimensioned below the recited micron thresholds, and (ii) a polymer composition that is ≥50/60/70 wt% polyethyl methacrylate ("PEMA").

Element (d) is the tell: the specification itself concedes this material is known commercial art — "A preferred material... is marketed as Pro3dure G10... This material is described in EP 3209265." That sentence is an express admission that the macromolecular composition of element (d) is prior art.

2. The operative prior art

2.1 Resin composition (element d) — EP 3209265 A1

The applicant's own specification attributes to EP 3209265 the whole of element (d): PEMA or PEMA–PMMA copolymer; ≥50/60/70 wt% PEMA/PEMA-PMMA; a second alkyl acrylate/methacrylate monomer; a flexibilizer (citric-acid, adipic-acid, phthalic-acid or aliphatic ester type, e.g. 1,2-cyclohexanedicarboxylic acid diisononyl ester); and a barbituric-acid or peroxide catalyst at 0.25–1 wt%. The patent does not claim to have invented the resin; it claims a device made using it. EP 3209265 is therefore essentially dispositive of element (d) standing alone, and the applicant's characterization of it is a binding admission.

2.2 Transparency + biocompatibility + SL printing — Urrios et al., Lab Chip 2016, 16, 2287–2294

"3D-printing of transparent bio-microfluidic devices in PEG-DA" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930360/). This is the closest non-patent art on elements (c) and much of (b):

• The authors state their design priority explicitly: "to produce 3D-printable devices that are water-impermeable, biocompatible, transparent, and cheap (by this order of priority)." That is element (c) in the authors' own words, six-plus months before the priority date.
• They demonstrate clean-room SL printing of fully transparent microfluidic devices, and culture CHO-K1 cells and primary hippocampal neurons for 48 hrs — i.e., non-cytotoxicity over a sustained exposure.
• They expressly identify the state of the art: "the performance of SL-printed devices is still inferior to that of equivalent PDMS devices," and diagnose the cause as "which components of commercial resins are responsible for the cytotoxicity and the transparency loss is very difficult because the resins have a proprietary formulation." This is the problem statement the challenged patent addresses.
• Their comparative table contrasts PDMS, micromilling, and SL on resolution, biocompatibility, bonding, 3D designs, and automated manufacturing — framing resolution and biocompatibility as the two co-equal, simultaneously-optimized variables.

2.3 Sub-100 µm resolution — Gong et al., Lab Chip 2017, 17, 2899–2909

"Custom 3D printer and resin for 18 µm × 20 µm microfluidic flow channels" (https://pubmed.ncbi.nlm.nih.gov/28726927/). Published Aug. 22, 2017 — eight days before the earliest priority date; squarely § 102(a)(1) art.

• "While there is great interest in 3D printing for microfluidic device fabrication, to-date the achieved feature sizes have not been in the truly microfluidic regime (<100 µm). In this paper we demonstrate that a custom DLP-SLA 3D printer and a specifically-designed, low cost, custom resin can readily achieve flow channel cross sections as small as 18 µm × 20 µm."
• Supplies the resin-engineering methodology for resolution: pixel/spot size (7.6 µm projection plane, 385 nm LED), UV-absorber selection from 20 candidates, a model for optical penetration depth, and a "channel narrowing technique."
• Conclusion: "3D printing is finally positioned to challenge the pre-eminence of methods such as soft lithography for microfluidic device prototyping and fabrication."

This reference is effectively an anticipation of the resolution element by disclosure of a species well below every recited threshold (18 µm and <25 µm, versus claim thresholds of "less than 100, 150, 200 or 250 microns").

2.4 Optically clear, biocompatible, fluorescence-imaged SL devices with ~100 µm features — Sugiura et al., MicroTAS 2015

"Stereolithography technique for fabrication of cell culture microfluidic devices," 19th Int'l Conf. on Miniaturized Systems (Oct. 25–29, 2015, Gyeongju, Korea) (https://www.rsc.org/images/LOC/2015/PDFs/Papers/2101_M.619i.pdf). This single paper is remarkable for how much of claim 1 it touches:

• "This paper reports stereolithography technique to fabricate microfluidic devices with optically clear and biocompatible cell culture microchambers."
• "we have investigated on the substrate, photocurable polymer resin, and fabrication process of stereolithography... report a method of stereolithography on a transparent substrate, which enabled us to fabricate optically clear and biocompatible microchambers."
• Resolution: "an in-plane resolution as small as 100 µm and thickness as small as 20 µm."
• Fluorescence capability (element c): "phase contrast images and fluorescence images were successfully taken in the microchambers fabricated by stereolithography" after 3 days of perfusion culture.
• Non-cytotoxicity: "We didn't observe any toxic effect of the materials used."

2.5 Transparent biocompatible SL resin class, including a methacrylate resin — Au et al., MicroTAS 2015

"Biocompatible 3D-printed PEG-diacrylate microfluidics" (Folch group) (https://www.rsc.org/images/LOC/2015/PDFs/Papers/1548_W.423f.pdf) states the state of the art directly:

"WaterShed XC 11122 stereolithography resin is optically-transparent, water-resistant, and has been certified to pass minimum biocompatibility requirements."

This is the linchpin for element (d). A commercially available, optically transparent, biocompatibility-certified methacrylate stereolithography resin was known to the field pre-2016. Substituting a PEMA-based methacrylate resin for a PEG-DA or WaterShed-type acrylate resin is squarely a substitution of one known material for another to obtain the same, known properties.

2.6 Monolithic integrated AM microfluidics — Gong, Woolley & Nordin, Lab Chip 2016, 16(13), 2450–2458

"High density 3D printed microfluidic valves, pumps, and multiplexers." Demonstrates monolithically printed, integrated active components (valves surviving 1,000,000 actuations; pumps at 40 µL/min) — undercutting any argument that "monolithic integration of channels, valves, pumps, ports, and bubble traps" (specification ¶ summarizing FIG. 8) was inventive.

2.7 Biocompatibility screening framework — Macdonald et al., Lab Chip 2016, 16, 291–297; Oskui et al., Environ. Sci. Technol. Lett. 2016, 3(1), 1–6

Both predate the priority date and teach the methods by which a POSA would screen printable photopolymers for cytotoxicity, and both are cited in the field's literature. Macdonald et al. (zebrafish embryo toxicity assays on 3D-printed photopolymers) and Oskui et al. ("Assessing and Reducing the Toxicity of 3D-Printed Parts") establish that cytotoxicity testing of SLA resins was routine and conventional by 2016 — a direct rebuttal to any "unpredictable results" argument.

2.8 The applicant's own cited references

Leonhardt et al. (2016) is cited by the applicant for cytotoxicity. US 2002/0182241 A1 and US 2011/0290113 A1 are cited in the specification as exemplars of lamination-fabricated, non-monolithic devices. Critically, the specification disparages those devices as "not result[ing] in monolithic structures" — but disparaging a fabrication route is not teaching away from a different AM route; it is an affirmative statement that AM was the known, preferred alternative.

3. Combination A (primary): Sugiura 2015 + Gong 2017 + EP 3209265

Claim chart:

Motivation to combine (articulated, per KSR Int'l v. Teleflex, 550 U.S. 398 (2007)):

1. Same field of endeavor, same problem, same solution space. All three references address 3D-printed photopolymer microfluidics. Sugiura and Gong both frame the objective the same way: match soft-lithography microfluidics using stereolithography. Both are directed to the very "problem" the patent's Background recites (transparency loss and toxicity of commercial resins, and inadequate feature resolution).
2. The references teach away from the combination's alleged difficulty, not toward it. Urrios diagnoses the problem as proprietary, unscreened resin formulations; Gong supplies the resin-formulation methodology (UV absorber, penetration depth, pixel size); Sugiura supplies the transparency/biocompatibility result. A POSA combining them has a complete roadmap.
3. Elements (c) and (d) are result-effective variables with predictable direction. Transparency, auto-fluorescence, and cytotoxicity are properties a POSA routinely measures (Macdonald; Oskui; Leonhardt) and routinely optimizes. Where the prior art identifies a property as desirable and provides a finite menu of candidate materials, selecting among them is "obvious to try." KSR, 550 U.S. at 421.
4. Finite, identified, predictable solutions. The patent's own working example screened exactly four commercially available printables (Pro3dure GR-10, WaterShed XC 11122, PlasCLEAR, MED610) against three printing platforms. Where "a finite number of identified, predictable solutions" exists, "a person of ordinary skill has good reason to pursue the known options within his or her technical grasp." KSR, 550 U.S. at 421.
5. The resin is a medical/implant-grade commercial product. Pro3dure GR-10 is, per the patent itself, "intended for manufacturing implant and bite splints." A resin qualified for long-term mucosal/body contact carries an inherent, a priori reasonable expectation of low cytotoxicity — supplying the "reasonable expectation of success" that In re Dow Chemical, 837 F.2d 469 (Fed. Cir. 1988), requires.
6. Simple substitution of a known material for a known purpose. Replacing a PEG-DA or WaterShed methacrylate SL resin with a PEMA-based methacrylate SL resin is a substitution of known materials having known functions in the same process — presumptively obvious under In re Fout, 675 F.2d 297 (CCPA 1982), absent a showing of criticality.

4. Combination B: Urrios 2016 + Gong 2017 + EP 3209265

If the examiner prefers the closest patent-quality, pre-priority, peer-reviewed art, Urrios is the stronger primary reference than Sugiura, because Urrios expressly recites all four of claim 1's element-(c) properties (water-impermeable, biocompatible, transparent, cheap) as the design objective, and expressly identifies the SL-resin-toxicity/transparency problem.

• Urrios supplies (c) in full, plus 3D-printed microfluidic channels and 48-hour cell culture.
• Gong supplies the <100 µm resolution element (a) and the technique-selection element (b), with 18 µm × 20 µm channels.
• EP 3209265 supplies element (d).

Motivation: Urrios' own stated goal — better SL microfluidic materials — is the motivation. A POSA reading Urrios would directly be motivated to test alternative commercially available SL resins, because Urrios says the problem is that "the resins have a proprietary formulation" and that identifying the toxic/opaque components is "very difficult." The natural, and indeed the only practical, solution to that stated problem is empirical screening of alternative commercially available resins. That is precisely what the applicant did — and what KSR says is not inventive.

5. Combination C: Gong 2016 (valves/pumps/multiplexers) + Sugiura/Urrios + EP 3209265

For any claim reciting monolithic integration of channels, valves, pumps, ports, or bubble traps (see §7), Gong's 2016 Lab Chip paper supplies monolithically 3D-printed, integrated, high-cycle-life valves and pumps. Combined with Sugiura/Urrios for optical/biocompatibility properties and EP 3209265 for the resin, this combination covers the "fully monolithic integrated device" theme.

6. Combination D: EP 3209265 as the linchpin of a § 102/§ 103 hybrid attack on element (d)

Because the specification expressly admits that the claimed PEMA/PEMA-PMMA composition is "described in EP 3209265," any rejection of element (d) can rest on the applicant's own admission, independent of whether EP 3209265 is § 102(a)(1) or § 102(a)(2) art (its publication date relative to Aug. 30, 2017 was not verifiable this session — flag: verify). Once (d) is conceded as known, the case collapses to whether using a known implant-grade transparent resin in a known AM microfluidic fabrication process to make a device with known dimensional requirements is inventive. Under KSR and In re Kubin, 561 F.3d 1351 (Fed. Cir. 2009), it is not.

7. Dependent / additional claims (flagged lower confidence — from third-party claim summary)

The claim summary at mtec-sc.org identifies these further limitations, and each is independently vulnerable:

8. Why the functional language of claim 1 does not save it

Three doctrines converge:

1. Printed matter / result recitations. "[S]elected to provide," "provides for non-cytotoxicity," "optical transparency," "reduced auto-fluorescence" state a result, not structure. In re Schreiber, 128 F.3d at 1477; In re Halliburton, 437 F.2d at 1029.
2. Inherency. Cytotoxicity, transparency, and auto-fluorescence are inherent physical properties of a given crosslinked polymer. A prior-art device made of the same polymer inherently possesses them. In re Best, 562 F.2d 1252 (CCPA 1977); In re Spada, 911 F.2d 705 (Fed. Cir. 1990).
3. Result-effective variable. Where the prior art recognizes a property as desirable and the claimed variation is a property the artisan would optimize, the burden is on the applicant to show criticality. In re Applied Materials, 692 F.3d 1289 (Fed. Cir. 2012).

9. The genuine counterarguments (why a § 103 rejection is not a certainty)

I flagged in the litigation section that this is recent grant with no known litigation; the same caution applies here. The applicant has two real arguments, and at least one is grounded in its own data:

1. Unexpected results — and a plausible teaching away. The patent's data show:

   • Of the screened resins, WaterShed XC 11122 was the better performer on resolution and CAD fidelity ("can resolve finer features than Pro3dure GR-10 and printed parts made in this resin have closer resemblance to the CAD file") — yet it "exhibits cytotoxicity."
   • MED610 "has comparable biocompatibility to that of Pro3dure GR-10" but its feature resolution is worse and its PolyJet support material "significantly complicates the post-processing."
   • Critically: "most photopolymerizable materials that are reportedly biocompatible exhibit obvious declines in biocompatibility by the 48-hour mark."

   The applicant can argue: the prior art (specifically Au/Folch 2015) expressly taught that WaterShed XC 11122 was "certified to pass minimum biocompatibility requirements" — so the field's leading transparent SL resin was believed biocompatible, and the applicant's data prove it is not. If the best-resolution transparent resin is cytotoxic and the papers report that "biocompatible" photopolymers fail by 48 hours, then the prior art teaches that transparent, high-resolution photopolymers are NOT predictably non-cytotoxic over extended periods — a teaching-away from the claimed combination, and evidence of unexpected results under In re Soni, 54 F.3d 746 (Fed. Cir. 1995). This is the applicant's strongest argument, and it is supported by the patent's Figure 3/4 data (described as "remarkable cellular compatibility" over 96 hours, matching the positive control).

2. The "long-term" qualifier. Claim 1 requires non-cytotoxicity "over an extended period of time," and dependent claims specify ≥90% survival over one week. Urrios's evidence is 48 hours; Sugiura's is 3 days; Macdonald's assays are short-term. If the applicant can show that none of the cited art teaches or suggests cytocompatibility beyond 48–72 hours, and that the field's expectation was failure in that window, the "extended period" limitation carries weight. This is the limitation the examiner must focus on.

Rebuttal to the rebuttal: (i) KSR's "obvious to try" applies with full force to screening a finite set of four commercially available, implant-grade resins; (ii) Pro3dure GR-10's stated intended use as an implant and bite-splint material supplies the reasonable expectation of long-term body-contact compatibility; (iii) routine optimization of a known property (cytotoxicity) via known assays (Macdonald; Oskui) does not become inventive merely because the artisan cannot predict a priori which candidate will win — that is the definition of "obvious to try"; (iv) the applicant's evidence of success is post-filing experimentation on a known commercial resin, which does not establish that the selection was non-obvious, only that the resin works — and EP 3209265 already disclosed the resin.

10. Bottom line and confidence

Assessment: Claim 1 is, on the record I can verify, more likely than not obvious under § 103, on the combination of Sugiura et al. (MicroTAS 2015) + Gong et al., Lab Chip 2017 + EP 3209265 A1, and alternatively Urrios et al., Lab Chip 2016 + Gong et al. 2017 + EP 3209265 A1. Element (d) is admitted prior art by the applicant's own specification. Element (a) is disclosed by Gong in species form (18 µm). Elements (b) and (c) are disclosed by Sugiura in substance, including fluorescence imaging of a 3-day cell culture in an "optically clear and biocompatible" SL microchamber. The remaining gap — "extended period" cytocompatibility — is the only genuinely contestable element, and it is a classic "obvious to try"/routine-optimization battleground.

Confidence: moderate. Rated down for three specific, non-trivial reasons:

1. I could not read WO 2017/027838 A1 or WO 2017/089963 A1, the two X-category references on the ISR. This is the single biggest gap. An X reference may anticipate claim 1 outright, which would moot the entire § 103 analysis. Do not finalize this opinion before reading them.
2. I have verbatim text for claim 1 only. The dependent-claim analysis in §7 rests on a third-party summary (mtec-sc.org), not the patent's own claims text. I did not verify, e.g., the exact wording of the second independent claim.
3. The publication date of EP 3209265 A1 relative to Aug. 30, 2017 was not verified this session. If it published after Aug. 30, 2017, element (d) must be attacked via § 102(a)(2) (if its effective filing date is earlier) or via the applicant's own admission, rather than § 102(a)(1).

Recommended next steps:

• Retrieve WO 2017/027838 A1 and WO 2017/089963 A1 full texts from PATENTSCOPE or Espacenet and map them claim-element by claim-element.
• Confirm EP 3209265 A1's publication date and effective filing/priority date.
• Pull the file wrapper (USPTO PatentCenter for application 17/700,031) to see what the examiner actually cited and how the applicant overcame it — the fastest route to understanding which reference was considered closest and which argument the applicant already made.
• Obtain the verbatim text of all 14 claims before rendering a final opinion.

Note on the litigation cross-reference: nothing in this § 103 analysis contradicts the litigation summary. The two are consistent (no litigation found; patent granted Jan. 28, 2025). The only flag is the one-day priority-date discrepancy (Aug. 30 vs. Aug. 29, 2017) noted in §0 — immaterial to the prior-art dates relied on here, since Gong et al. published Aug. 22, 2017.